Annual Congress Vienna 2009

---

---

Clinical Trials: "Aerosolized Lancovutide (Moli1901)" and "Oral Sildenafil"

Symposium
Chairs: T. Ferkol (St-Louis, United States of America), J. O. Warner (London, United Kingdom)
Aims: Aerosolized Lancovutide (Moli1901): 1. to assess the efficacy and safety of 8 weeks treatment with 3 different dosage schedules of aerosolized Lancovutide in adolescents (12 years or older) and adults with cystic fibrosis 2. to establish the minimum effective dose, optimal dose and maximum safe dose (change of FEV1) and tolerability of aerosolized Lancovutide in cystic fibrosis patients.
Oral Sildenafil: 1. to assess the efficacy of 16 weeks of chronic treatment with oral sildenafil in paediatric subjects, aged 1 to 17 years, with pulmonary arterial hypertension (PAH). 2. to assess safety, tolerability, and pharmacokinetics of 16 weeks of chronic treatment with oral sildenafil in paediatric patients, aged 1 to 17 years with PAH, and to assess the survival status of patients who did not enter A1481156.

Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study R. Barst (Scarsdale, Ny, United States of America)
Comments on Clinical Trial (Independent view) V. Cottin (Lyon, France)